GDF15-Treated iPSC-MSC-Derived Exosomes Alleviate Fibrosis Post-Myocardial Infarction via Repression of the MFAP4/ERK/Drp1 Axis - PubMed
4 hours ago
- #exosomes
- #mitochondrial fission
- #cardiac fibrosis
- GDF15-treated iPSC-MSC-derived exosomes (GDF15-iPSC-MSC-EXOs) reduce fibrosis post-myocardial infarction (MI) by inhibiting the MFAP4/ERK/Drp1 pathway.
- Exosomes from GDF15-treated iPSC-MSCs show stronger anti-fibrotic effects compared to untreated exosomes in both in vivo and in vitro models.
- GDF15-iPSC-MSC-EXOs prevent mitochondrial fission in cardiac fibroblasts (CFs), which is crucial for reducing fibrosis.
- The study identifies MFAP4 as a direct target of GDF15, leading to repression of the ERK/Drp1 axis and reduced fibrosis.
- GDF15 pretreatment enhances the therapeutic potential of iPSC-MSC-derived exosomes for cardiac fibrosis post-MI.